| Message: | Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking . Acomplia, along with CB1 receptors, reduces the EC system's over-activity.
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
Web: www.rawsgear.com
Web: www.rawsgearpharma.com
Email: gear@quality-steroid.com
Skype: +8615711952876
Whatsapp +8615711952876 |
my account
